Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk’s Wegovy oral weight-loss drug.
Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor
